Acrongenomics Inc. is a publicly trading company under the symbol AGNM. The mission of the Company is developing the “BioLED Technology Platform”, through a joint development agreement with Molecular Vision Ltd. A unique platform technology integrating microfluidics, polymer light emitting diodes “pLED’s” and optical photodetectors. It is intended that this platform becomes a de-facto standard for unlimited applications in the Point-of-Care (PoC) portable Diagnostics field. As an integrated PoC diagnostic testing device the users will be in the Decentralised testing segments of the market where immediate test results can affect the treatment or therapy and change current patient pathways. The driving force for acceptance will be the improved patient treatment and the saving of significant healthcare costs.

The Portable Diagnostic Device will allow testing outside the traditional laboratory environments in places such as:

Physician’s offices                 
Independent Clinics               
Emergency services    
Hospitals (ER, ICU, Operating Room)
Home testing
Developing countries and places without large central laboratories 

Acrongenomics has the exclusive, worldwide, perpetual license in the high growth clinical testing areas of:

Diabetes Management/Kidney function,
Cardiovascular Disease
Substance of Abuse, DOA

In addition to the abovementioned fields, Acrongenomics has also acquired 10.9% of the shares of Molecular Vision.

The Company intends to gain a significant position in the In Vitro Diagnostic (IVD) market through the technologies it has identified. The initial focus will be on human health but the technology has scope to be applied in other areas of diagnostic testing.